Ainos (AIMD) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Voting matters and shareholder proposals
Ratification of KCCW Accountancy Corp. as independent registered public accounting firm for fiscal year ending December 31, 2024 is up for vote.
Approval sought for reservation of up to 2 million shares of common stock as special stock awards, not under the 2023 Stock Incentive Plan, per Nasdaq Listing Rule 5635(c).
Other business may be addressed as appropriate during the meeting or any adjournment.
Audit committee and external auditor matters
KCCW Accountancy Corp. recommended for ratification as the external auditor for the upcoming fiscal year.
Shareholder rights and capital structure
Shareholders are invited to vote online or in person at the annual meeting scheduled for September 27, 2024.
Up to 2 million shares of common stock may be reserved for special stock awards, impacting potential dilution and capital structure.
Latest events from Ainos
- AI Nose is scaling as an AI perception platform, targeting industrial and robotics growth in 2026.AIMD
Fireside chat2 Feb 2026 - Secondary offering of 6.7M shares enables liquidity for stockholders, no proceeds to company.AIMD
Registration Filing16 Dec 2025 - Registration enables resale of 6.7M+ shares from various agreements and awards.AIMD
Registration Filing16 Dec 2025 - Shareholders will vote on auditor ratification, special stock awards, and meeting adjournment.AIMD
Proxy Filing2 Dec 2025 - Annual meeting to vote on directors, auditor, special stock awards, and key governance matters.AIMD
Proxy Filing2 Dec 2025 - AI Nose commercialization and cost reductions narrowed Q3 2025 net loss as revenue grew.AIMD
Q3 202513 Nov 2025 - AI Nose rollout drove first revenues, a $2.1M order, and positive gross margin despite wider losses.AIMD
Q2 202513 Aug 2025 - Q2 net loss rose to $3.2M as revenue dropped to zero and drug development accelerated.AIMD
Q2 202413 Jun 2025 - Q3 net loss rose 24% to $3.7M as Ainos pivots from COVID-19 kits to new clinical products.AIMD
Q3 202413 Jun 2025